Literature DB >> 1486740

Serum N terminal procollagen III fragment: a predictive marker of joint destruction in rheumatoid arthritis?

J G Tebib1, P Viguier, E Noel, F Colson, Y Barbier, M Bouvier.   

Abstract

The level of the N terminal fragment of procollagen III (P3NP) levels of 100 consecutive patients affected by rheumatoid arthritis (RA) were evaluated in comparison with disease activity markers (erythrocytes sedimentation rate, C reactive protein), immunological status (rheumatoid factors, immune complexes) and joint destruction (assessed according to the Steinbrocker index). P3NP levels showed no significant relationship either to disease activity or to immunological status; however, a strong association was fond between X-ray grade and P3NP values. A two-year retrospective study of 32 patients belonging to the original 100 patient population allowed us to assign a predictive value for joint destruction to the P3NP level in the early stage of the disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1486740     DOI: 10.1007/bf02283106

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  Course and prognosis in rheumatoid arthritis.

Authors:  J J DUTHIE; P E BROWN; J D KNOX; M THOMPSON
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103

Review 2.  Rheumatoid arthritis. Pathophysiology and implications for therapy.

Authors:  E D Harris
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

3.  Circulating hyaluronate in rheumatoid arthritis: relationship to inflammatory activity and the effect of corticosteroid therapy.

Authors:  A Engström-Laurent; R Hällgren
Journal:  Ann Rheum Dis       Date:  1985-02       Impact factor: 19.103

4.  Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response.

Authors:  P W Thompson; A J Silman; J R Kirwan; H L Currey
Journal:  Arthritis Rheum       Date:  1987-06

5.  Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine.

Authors:  K Hørslev-Petersen; K D Bentsen; A Engström-Laurent; P Junker; P Halberg; I Lorenzen
Journal:  Ann Rheum Dis       Date:  1988-02       Impact factor: 19.103

6.  Serum aminoterminal type III procollagen peptide in early rheumatoid arthritis: relation to disease activity and progression of joint damage.

Authors:  K Eberhardt; L Thorbjorn Jensen; K Horslev-Petersen; H Pettersson; I Lorenzen; F Wollheim
Journal:  Clin Exp Rheumatol       Date:  1990 Jul-Aug       Impact factor: 4.473

7.  Connective tissue metabolites in serum as markers of disease activity in patients with rheumatoid arthritis.

Authors:  K Hørslev-Petersen; K D Bentsen; P Halberg; P Junker; K I Kivirikko; K Majamaa; L Risteli; J Risteli; I Lorenzen
Journal:  Clin Exp Rheumatol       Date:  1988 Apr-Jun       Impact factor: 4.473

8.  Significance of positive tests for rheumatoid factor in the prognosis of rheumatoid arthritis. A follow-up study.

Authors:  A Cats; H M Hazevoet
Journal:  Ann Rheum Dis       Date:  1970-05       Impact factor: 19.103

9.  The aminoterminal-type-III procollagen peptide and proteoglycans in serum and synovial fluid of patients with rheumatoid arthritis or reactive arthritis.

Authors:  K Hørslev-Petersen; T Saxne; D Haar; B S Thomsen; K D Bentsen; P Junker; I Lorenzen
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

10.  Prospective study of early rheumatoid arthritis. I. Prognostic value of IgA rheumatoid factor.

Authors:  I Teitsson; R H Withrington; M H Seifert; H Valdimarsson
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

View more
  1 in total

1.  Molecular serum markers of liver fibrosis.

Authors:  Tianhui Liu; Xiaoming Wang; Morten A Karsdal; Diana J Leeming; Federica Genovese
Journal:  Biomark Insights       Date:  2012-07-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.